Quarterly pharmacy formulary change notice

Similar documents
Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET BYDUREON BCISE 2 MG/0.

HEALTH SHARE/PROVIDENCE (OHP)

Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria

AETNA BETTER HEALTH January 2017 Formulary Change(s)

Step Therapy Criteria

AETNA BETTER HEALTH January 2017 Formulary Change(s)

Quarterly Pharmacy Formulary Change Notice

Aetna Better Health of Illinois Medicaid Formulary Updates

Health Partners Medicare Prime 2019 Formulary Changes

Quarterly pharmacy formulary change notice

THERAPEUTIC AREA NAME STRENGTH DOSAGE FORM

2018 CareOregon Advantage Part D Formulary Changes

2018 Step Therapy Criteria (List of Step Therapy Criteria)

March 2018 P & T Updates

HOW TO USE THE FORMULARY

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements

2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements

Quarterly pharmacy formulary change notice

Health Partners Medicare Special 2018 Formulary Changes

Drugs That Require Step Therapy (ST) Step Therapy Medications

Neighborhood Medicaid Formulary Changes: June 2017

2018 Step Therapy (ST) Criteria

Step Therapy Requirements

2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates

2017 Step Therapy (ST) Criteria

San Francisco Health Plan (SFHP)

San Francisco Health Plan (SFHP)

DPP4 INHIBITORS. Products Affected Step 2: Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet

Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir

Drugs That Require Step Therapy (ST) Step Therapy Medications

Drugs That Require Step Therapy (ST) Step Therapy Medications

Emblem Medicaid 3Q18 Formulary Updates

ALPHA BLOCKERS. Products Affected Step 1: Details. Step 2: Rapaflo 4 mg capsule Rapaflo 8 mg capsule

Drugs That Require Step Therapy (ST) Step Therapy Medications

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

ANTICONVULSANT STEP THERAPY

Quarterly pharmacy formulary change notice

San Francisco Health Plan (SFHP)

2018 Step Therapy Criteria (List of Step Therapy Criteria)

Contents ALPHA BLOCKERS... 3 COLCRYS-PST... 4 DPP-4 INHIBITORS-PST... 5 HIGH RISK MEDICATIONS - SEDATIVE HYPNOTICS... 6

Date: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes

Oregon Health Plan prescription benefit updates

Provider update: Quarterly pharmacy formulary change notice

DPP4 INHIBITORS. Details. Step Therapy Criteria Health Alliance Plan 2019 Date Effective: 04/01/2019

Step Therapy Requirements. Effective: 11/01/2018

Drugs That Require Step Therapy (ST) Step Therapy Medications

Quarterly Pharmacy Formulary Change Notice

Added, Removed or Changed. Added, Removed or Changed

ELEVATE. Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard)

Advanced Control Formulary Change Summary Report Effective

Peach State Health Plan routinely reviews the medications available on the Preferred Drug

ATYPICAL ANTIPSYCHOTICS

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.

Prescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)

Step Therapy Requirements. Effective: 05/01/2018

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT MAY 29, 2012

Fee-for-Service Pharmacy Provider Notice #216 ** March 2016 PDL Changes ** Existing Drug Classes

Formulary Medical Necessity Program

3 Tier Formulary Additions

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

2018 Medicare Part D Formulary Change

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Optima Tier Gold Formulary Date Effective: November 1, 2018.

THERAPEUTIC AREA NAME STRENGTH DOSAGE FORM

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

2018 Formulary Update

Step Therapy Requirements

Step Therapy Criteria 2019

Texas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018

Amerigroup Washington, Inc. to conduct postservice reviews of certain modifiers and services

Quarterly pharmacy formulary change notice

2018 Formulary Notice of Change Prescription Drug Plans

Notice of Mid-Year Changes to 2019 Paramount Enhanced Formulary

Texas Prior Authorization Program Clinical Edit Criteria

Pharmacologic Agents for Treatment of Type 2 Diabetes

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

Quarterly pharmacy formulary change notice

List 1 PRESCRIPTION DRUGS REQUIRING PRE-AUTHORIZATION LIBERTY HEALTH DRUG IDENTIFICATION NUMBER (DIN)

Transcription:

Quarterly pharmacy formulary change notice Provider update Summary: Effective August 1, 2018, the preferred formulary changes detailed in the table below will apply to District of Columbia Healthy Families Program, Alliance and Immigrant Children s Program members. Additionally, effective August 1, 2018, there will be changes to the nonpreferred and prior authorization (PA) requirements of these formulary items. These formulary changes were reviewed and approved at the first-quarter 2018 Pharmacy and Therapeutics Committee meeting. Formulary changes effective August 1, 2018 Therapeutic class Medication Formulary status change INSULIN INSULIN INSULIN (EDIT ONLY) APIDRA 100 UNITS/ML VIAL APIDRA SOLOSTAR 100 UNITS/ML ADMELOG 100 UNIT/ML VIAL ADMELOG SOLOSTAR 100 UNIT/ML HUMULIN R 500 UNITS/ML VIAL HUMULIN R 500 UNITS/ML KWIKPEN EFFECTIVE FOR NEW STARTS ON 8/1/18; EFFECTIVE FOR CURRENT UTILIZERS ON 10/1/18 PREFERRED 30 MLS PER 30 DAYS ADDING PA TO PREFERRED PRODUCT Potential alternatives (preferred products) ADMELOG 100 UNIT/ML VIAL ADMELOG SOLOSTAR 100 UNIT/ML ANTIPERSPIRANTS HYPERCARE 15% SOLUTION PREFERRED DPP4s GLP1s GLP1s JENTADUETO 2.5 MG-1000 MG TAB JENTADUETO 2.5 MG-500 MG TAB JENTADUETO 2.5 MG-850 MG TAB JENTADUETO XR 2.5 MG-1,000 MG JENTADUETO XR 5 MG-1,000 MG TB TRADJENTA 5 MG TABLET TANZEUM 30 MG PEN INJECT TANZEUM 50 MG PEN INJECT OZEMPIC 0.25-0.5 MG DOSE PEN OZEMPIC 1 MG DOSE PEN PREFERRED WITH STEP THERAPY EFFECTIVE 4/1/18 JANUVIA JANUMET XR ST APPLIES OZEMPIC VICTOZA ST APPLIES https://providers.amerigroup.com DCPEC-0558-18 June 2018

ICS/LABA ICS/LABA IRON SUPPLEMENTS MISCELLANEOUS ANTINEOPLASTIC DRUGS MISCELLANEOUS OPHTHALMOLOGICS (AUTHORIZED GENERIC OF AIRDUO RESPICLICK) FLUTICASONE-SALMETEROL 55-14 FLUTICASONE-SALMETEROL 113-14 FLUTICASONE-SALMETEROL 232-14 DULERA 100 MCG/5 MCG INHALER DULERA 200 MCG/5 MCG INHALER POLY-VI-SOL WITH IRON DROPS POLY-VI-SOL DROPS MITOXANTRONE 20 MG/10 ML VIAL MITOXANTRONE 25 MG/12.5 ML VL MITOXANTRONE 30 MG/15 ML VIAL IMMUNOMODULATORS PROLEUKIN 22 MILLION UNIT VIAL PREFERRED CURRENT UTILIZERS WILL BE GRANDFATHERED PREFERRED COVERED *AUTHORIZED GENERIC FOR AIRDUO RESPICLK FLUTICASONE- SALMETEROL BREO ELLITA VISUDYNE 15 MG VIAL COVERED ADD PA LAMA/LABA STIOLTO RESPIMAT INHAL SPRAY PREFERRED PHOSPHATE BINDERS PHOSPHATE BINDERS LANTHANUM CARB 500 MG TAB CHEW LANTHANUM CARB 750 MG TAB CHEW LANTHANUM CARB 1,000 MG TB CHW SEVELAMER 0.8 GM POWDER PACKET SEVELAMER 2.4 GM POWDER PACKET SEVELAMER CARBONATE 800 MG TAB VELPHORO 500 MG CHEWABLE TAB PREFERRED WITH PA CURRENT UTILIZERS WILL BE GRANDFATHERED ELIPHOS 667 MG TABLET CALCIUM ACETATE 667 MG LANTHANUM CHEW TAB SEVELAMER TAB/PACKET Page 2 of 6

PRENATAL VITAMINS GENERIC OTC PRODUCTS ONLY PREFERRED PRENATAL VITAMINS BRAND OTC ALL RX PRODUCTS CURRENT UTILIZERS WILL BE GRANDFATHERED EDITS No changes in preferred/nonpreferred status revision or addition to UM edit only. ANTICONVULSANTS ZONEGRAN 100 MG CAPSULE 1 CAPSULE PER DAY ANTIBIOTICS BAXDELA 450 MG TABLET 28 TABLETS PER FILL; 1 FILL PER 30 DAYS ADD AL COUGH AND COLD COUGH AND COLD PRODUCTS MEMBERS EQUAL TO CONTAINING HYDROCODONE OR LESS THAN 18 REQUIRE PA COUGH AND COLD ANTIVIRALS ANTIVIRALS COUGH AND COLD PRODUCTS CONTAINING CODEINE PREVYMIS 240 MG/12 ML VIAL PREVYMIS 480 MG/24 ML VIAL PREVYMIS 240 MG TABLET PREVYMIS 480 MG TABLET ADD AL MEMBERS EQUAL TO OR LESS THAN 18 REQUIRE PA 1 VIAL PER DAY 100 DAYS OF TREATMENT 100 DAYS OF TREATMENT ASTHMA XOPENEX 30 VIALS 90 VIALS PER 30 DAYS ATYPICAL ANTIPSYCHOTICS BILE ACIDS CANCER AGENTS CANCER AGENTS CANCER AGENTS CONSTIPATION AGENTS COPD ABILIFY MYCITE CHENODAL 250 MG TABLET ALUNBRIG 180 MG TABLET ALUNBRIG 90 MG-180 MG TAB PACK ALUNBRIG 90 MG TABLET SYMPROIC 0.2 MG TABLET BROVANA 15 MCG/2 ML SOLUTION PA REQUIRED 7 TABLETS PER DAY 1 PACK IN 30 DAYS REVISED QL 2 TABLETS DAILY 2 VIALS (4ML) PER DAY GENERIC OTC PRENATALS Page 3 of 6

COPD COPD COPD PERFOROMIST 20 MCG/2 ML SOLN LONHALA MAGNAIR 25 MCG STARTER LONHALA MAGNAIR 25 MCG REFILL GLP-1 RECEPTOR AGONIST OZEMPIC 0.25-0.5 MG DOSE PEN GLP-1 RECEPTOR AGONIST HEPATITIS C TREATMENT AGENTS ICS ICS LIPID/CHOLESTEROL LOWERING AGENTS NEUROLOGICAL THERAPY NEUROLOGICAL THERAPY NEUROLOGICAL THERAPY OZEMPIC 1 MG DOSE PEN PEGINTRON 50 MCG KIT PEGASYS 180 MCG/0.5 ML SYRINGE PEGASYS 180 MCG/ML VIAL PEGASYS PROCLICK 180 MCG/0.5 PEGASYS PROCLICK 135 MCG/0.5 QVAR REDIHALER 40 MCG QVAR REDIHALER 80 MCG FLOLIPID NUEDEXTA 20-10 MG CAPSULE INGREZZA 40 MG CAPSULE INGREZZA 80 MG CAPSULE NEUROPATHIC PAIN LYRICA 82.5 NEUROPATHIC PAIN LYRICA 165 NEUROPATHIC PAIN LYRICA 330 PANCREATIC ENZYMES PANCREATIC ENZYMES POTASSIUM SPARING DIURETICS PROGESTINS PERTZYE DR 24,000 UNIT CAPSULE VIOKASE CAROSPIR 25 MG/5 ML SUSPENSION CRINONE 4% GEL CRINONE 8% GEL 2 VIALS (4ML) PER DAY 1 KIT PER 30 DAYS 1 PER 30 DAYS 1 PEN PER 28 DAYS 2 PENS PER 28 DAYS REMOVE PA 1 INHALER PER 30 DAYS 2 INHALERS PER 30 DAYS 5MLS PER DAY 2 CAPSULES PER DAY REVISED QL 1 CAPSULE PER DAY 1 CAPSULE PER DAY 25 CAPSULES PER DAY 25 TABLETS PER DAY ADD PA AND QL 20ML PER DAY 1 APPLICATORFUL PER DAY Page 4 of 6

PSYCHOTHERAPEUTIC AGENTS PULMONARY ARTERIAL HYPERTENSION SGLT2 SGLT2 SGLT2 SGLT2/DPP-4 INHIBITOR SUBSTANCE USE DISORDERS ADZENYS ER 1.25 MG/ML SUSP TRACLEER 32 MG TABLET FOR SUSP XIGDUO XR 2.5 MG-1,000 MG TAB STEGLATRO 5 MG TABLET STEGLATRO 15 MG TABLET SEGLUROMET 7.5-1,000 MG TABLET SEGLUROMET 2.5-500 MG TABLET SEGLUROMET 7.5-500 MG TABLET SEGLUROMET 2.5-1,000 MG TABLET STEGLUJAN 5-100 MG TABLET STEGLUJAN 15-100 MG TABLET SUBLOCADE 300 MG/1.5 ML SYRING SUBLOCADE 100 MG/0.5 ML SYRING LOPROX 0.77% CREAM LOTRIMIN ULTRA 1% CREAM NYSTATIN 100,000 UNIT/GM CREAM NYSTATIN 100,000 UNITS/GM OINT KETOCONAZOLE 2% CREAM OXISTAT 1% CREAM 15ML PER DAY 32 MG TABS FOR SUSP 4 TABLETS PER DAY 2 TABLETS PER DAY 2 TABLETS PER DAY 1 SYRINGE EVERY 28 DAYS 90 GMS PER 30 DAYS 30 GMS PER 30 DAYS 120 GMS PER 30 DAYS 60 GMS PER 30 DAYS What action do I need to take? Please review these changes and work with members to transition them to formulary alternatives. If you determine preferred formulary alternatives are not clinically appropriate for specific members, you will need to obtain PA to continue coverage beyond the applicable effective date. What if I need assistance? We recognize the unique aspects of members cases. If for medical reasons a member cannot be converted to a formulary alternative, call our Pharmacy department at 1-800-454-3730 and follow the voice prompts for pharmacy PA. Page 5 of 6

You can find the Preferred Drug List on our provider website at https://providers.amerigroup.com/dc > Pharmacy. If you need assistance with any other item, contact your local Provider Relations representative or call Provider Services at 1-800-454-3730. Page 6 of 6